neoantigen reactive t cells

Cell therapyexperimental

Clinical trial activity

7 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Aug 31, 2013 (NCT01967706)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • neoantigen reactive t cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06904066Phase 1Dec 2, 2025National Cancer Institute (NCI)
NCT04536922Phase 2Jan 27, 2021National Cancer Institute (NCI)
NCT03412877Phase 2Sep 6, 2018National Cancer Institute (NCI)
NCT03199807Phase 1/Phase 2 (Phase 2)Jul 20, 2017Nanjing University
NCT03171220Phase 1/Phase 2 (Phase 2)Jun 1, 2017Nanjing Medical University, Nanjing University
NCT01967706N/AAug 31, 2013Ageo Medical Clinic, Philip Morris
NCT04194190N/ANational Institutes of Health (NIH)
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3322018
Nanjing UniversityAcademic/Hospital2212017
Ageo Medical ClinicAcademic/Hospital1012013
Nanjing Medical UniversityAcademic/Hospital1012017
National Institutes of Health (NIH)Government111
Philip MorrisFor profit1112013
6 organizations
Page 1 / 1